These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26251675)

  • 1. MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.
    Vella S; Pomella S; Leoncini PP; Colletti M; Conti B; Marquez VE; Strillacci A; Roma J; Gallego S; Milano GM; Capogrossi MC; Bertaina A; Ciarapica R; Rota R
    Clin Epigenetics; 2015; 7(1):82. PubMed ID: 26251675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
    Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
    Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
    Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
    Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.
    Megiorni F; Cialfi S; McDowell HP; Felsani A; Camero S; Guffanti A; Pizer B; Clerico A; De Grazia A; Pizzuti A; Moles A; Dominici C
    BMC Cancer; 2014 Nov; 14():880. PubMed ID: 25427715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells.
    Beccafico S; Morozzi G; Marchetti MC; Riccardi C; Sidoni A; Donato R; Sorci G
    Carcinogenesis; 2015 Sep; 36(9):1071-83. PubMed ID: 26153023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.
    Marchesi I; Sanna L; Fais M; Fiorentino FP; Giordano A; Bagella L
    J Cell Physiol; 2018 Mar; 233(3):2360-2365. PubMed ID: 28722764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
    Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
    J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
    Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
    Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma.
    Taulli R; Foglizzo V; Morena D; Coda DM; Ala U; Bersani F; Maestro N; Ponzetto C
    Oncogene; 2014 May; 33(18):2354-62. PubMed ID: 23728344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A GRIP-1-EZH2 switch binding to GATA-4 is linked to the genesis of rhabdomyosarcoma through miR-29a.
    Song YL; Yang MH; Zhang S; Wang H; Kai KL; Yao CX; Dai FF; Zhou MJ; Li JB; Wei ZR; Yin Z; Zhu WG; Xue L; Zang MX
    Oncogene; 2022 Dec; 41(49):5223-5237. PubMed ID: 36309571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
    Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
    Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-27a Contributes to Rhabdomyosarcoma Cell Proliferation by Suppressing RARA and RXRA.
    Tombolan L; Zampini M; Casara S; Boldrin E; Zin A; Bisogno G; Rosolen A; De Pittà C; Lanfranchi G
    PLoS One; 2015; 10(4):e0125171. PubMed ID: 25915942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
    Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
    Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development.
    Tao T; Liu D; Liu C; Xu B; Chen S; Yin Y; Ang L; Huang Y; Zhang X; Chen M
    Biochim Biophys Acta; 2014 Sep; 1839(9):858-65. PubMed ID: 25017995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells.
    Huot M; Caron M; Richer C; Djibo R; Najmanovich R; St-Onge P; Sinnett D; Raynal NJM
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):845-856. PubMed ID: 34331108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.
    Li CH; Xiao Z; Tong JH; To KF; Fang X; Cheng AS; Chen Y
    Int J Cancer; 2017 Jan; 140(1):120-129. PubMed ID: 27594424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pannexin 1 inhibits rhabdomyosarcoma progression through a mechanism independent of its canonical channel function.
    Xiang X; Langlois S; St-Pierre ME; Barré JF; Grynspan D; Purgina B; Cowan KN
    Oncogenesis; 2018 Nov; 7(11):89. PubMed ID: 30459312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.